Controlled-Release Codeine Is Equivalent to Acetaminophen Plus

Total Page:16

File Type:pdf, Size:1020Kb

Controlled-Release Codeine Is Equivalent to Acetaminophen Plus 216 GENERAL ANESTHESIA Controlled-release codeine is equivalent to aceta- minophen plus codeine for post-cholecystectomy analgesia [La codéine à libération contrôlée est équivalente à de l’acétaminophène plus de la codéine pour l’analgésie postcholécystectomie] Frances Chung MD,* Doris Tong MD,* Paula C. Miceli MSc,† Joseph Reiz BSc,† Zoltan Harsanyi MBA,† Andrew C. Darke PhD,† Lance W. Payne PHARMD† Purpose: Following ambulatory surgery, long-acting analgesics may Objectif : En chirurgie ambulatoire, les analgésiques postopératoires provide advantages over short-acting analgesics. This study com- d’action prolongée peuvent avoir des avantages sur les analgésiques pared controlled-release codeine (CC) and acetaminophen plus d’action brève. Nous comparons la codéine à libération contrôlée (CC) codeine (A/C; 300 mg/30 mg) for pain control in the 48-hr period et une combinaison d’acétaminophène et de codéine (A/C ; 300 following laparoscopic cholecystectomy. mg/30 mg) comme analgésique pendant 48 h après une cholécystec- Methods: Eligible patients were randomized to CC or A/C in a tomie laparoscopique. double-blind, double-dummy parallel group study. Unrelieved pain Méthode : Des patients admissibles à l’expérimentation ont reçu de in hospital was treated with fentanyl iv bolus. Pain [100 mm visual la CC ou de l’A/C lors d’une étude à double insu, à double placebo en analogue scale (VAS)] was assessed before the first dose of medica- contrôle parallèle. À l’hôpital, la douleur tenace a été traitée avec des tion; at 0.5, one, two, three, and four hours post-dose; at dis- bolus iv de fentanyl. La douleur [échelle visuelle analogique (EVA) de charge; and three times a day for 48 hr. Adverse events were 100 mm] a été évaluée avant la première dose de médicament ; à recorded and measures of patient satisfaction were assessed at the 0,5, une, deux, trois et quatre heures après la dose ; au moment du end of the study. départ et trois fois par jour pendant 48 h. Les événements indésirables ont été notés et des mesures de la satisfaction du patient ont été Results: Eighty-four patients were enrolled in the study; 42 faites à la fin de l’étude. patients in each group. There were no statistically significant differ- ences between CC and A/C treatment. Mean VAS baseline pain Résultats : L’étude a été réalisée auprès de 84 patients : 42 dans chaque groupe. Il n’y a pas eu de différence statistiquement significa- was similar in both groups (P = 0.49) and there was no significant tive entre les traitements à la CC ou à l’A/C. La douleur initiale difference in the time to onset of analgesia (P = 0.17). At 0.5 hr, moyenne a été similaire dans les deux groupes (P = 0,49) et il n’y a the mean VAS pain score was significantly reduced from baseline in pas eu de différence significative de temps précédant le début de both groups (P = 0.0001). The VAS pain scores at discharge were l’analgésie (P = 0,17). À 0,5 h, le score de douleur moyen à l’EVA reduced 59% and 56% from baseline, respectively (P = 0.61). était significativement réduit dans les deux groupes (P = 0,0001). Les There was no difference between treatments in the incidence of scores à l’EVA au départ de l’hôpital ont été respectivement réduits de adverse events and patients reported similar levels of satisfaction. 59 % et de 56 % par rapport aux mesures initiales de la douleur (P Conclusions: Controlled-release codeine provides an equivalent = 0,61). Aucune différence intergroupe dans l’incidence d’événe- onset of analgesia, reduction in postoperative pain, and level of ments indésirables n’a été notée et la satisfaction des patients était patient satisfaction, to acetaminophen plus codeine, over 48 hr fol- comparable d’un groupe à l’autre. lowing cholecystectomy, with the advantage of less frequent dosing. Conclusion : La codéine à libération contrôlée offre un délai d’in- stallation de l’analgésie, une réduction de la douleur postopératoire et un niveau de satisfaction équivalents à une combinaison d’acéta- minophène et de codéine pendant 48 h après une cholécystectomie, et ce, avec l’avantage d’un dosage moins fréquent. From the Department of Anesthesia,* Toronto Western Hospital, University of Toronto, Toronto; and Purdue Pharma,† Pickering, Ontario, Canada. Address correspondence to: Dr. Frances Chung, Department of Anesthesia, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada. Phone: 416-603-5118; Fax: 416-603-6494; E-mail: [email protected] This study was partially supported by a grant from Purdue Pharma (Canada) Inc. Accepted for publication May 29, 2003. Revision accepted December 1, 2003. CAN J ANESTH 2004 / 51: 3 / pp 216–221 Chung et al.: CONTROLLED RELEASE CODEINE 217 APAROSCOPIC cholecystectomy is the available as 50, 100, 150 and 200 mg controlled- surgical treatment of choice for symptomatic release tablets, which is designed to provide controlled cholecystolithiasis and can be used in more delivery of codeine over a 12-hr period. It is current- L than 90% of cases.1,2 Over 37,000 laparo- ly the only controlled-release opioid marketed in scopic cholecystectomy procedures were performed in Canada for the treatment of mild to moderate pain. Canadian facilities during the fiscal year 2000–2001.3 The controlled-release formulation has demonstrated The laparoscopic approach to cholecystectomy has equivalent bioavailability to immediate-release tablet shortened the in-hospital recovery period following or liquid codeine formulations in single dose and surgery from one to three days to same-day dis- steady-state studies.21 In acute pain models, the medi- charge.4,5 Discharge time is dependent, in part, on the an time to onset of analgesia with controlled-release rate of recovery from anesthesia and the provision of codeine was 30 to 40 min, similar to immediate- appropriate postoperative analgesia.6,7 Unanticipated release preparations. admissions due to inadequate pain have enormous Following ambulatory surgery, long-acting anal- medical, social and cost implications.7 Therefore, the gesics may have advantages compared to short-acting aim of an analgesic technique should be not only to analgesics. The study was designed to evaluate the reduce post-laparoscopic pain, but also to facilitate ear- efficacy, safety and benefits of controlled-release lier mobilization, reduce perioperative complications, codeine compared with acetaminophen plus codeine and increase patient satisfaction.7 in the control of postoperative pain following laparo- Following laparoscopic cholecystectomy, patients scopic cholecystectomy. tend to report parietal,8 visceral9 and shoulder pain.10,11 Visceral pain is predominant during the first few post- Methods operative hours. The major groups of drugs used in the The study was conducted at the day surgery unit treatment of postoperative pain are opioid anal- (DSU), Toronto Western Hospital. Male and female gesics,12–15 and non-steroidal anti-inflammatory drugs.7 patients ($ 18 yr) scheduled to undergo laparoscopic Moderate to severe pain may follow laparoscopic chole- cholecystectomy were eligible for enrollment. Both cystectomy and often necessitates the use of opioid the general and local anesthesia during the procedure analgesics.7 Opioids may be administered by a variety of were standardized for all patients. routes; oral dosing is usually the most convenient and Study patients were admitted to the postanesthetic least expensive. It is appropriate as soon as the patient care unit (PACU) following surgery and later trans- can tolerate oral intake and is the mainstay of pain man- ferred to the DSU for complete recovery before being agement in the ambulatory surgical population.16 discharged home. When patients reported a visual Since the most severe pain following laparoscopic analogue scale (VAS) pain intensity > 40 mm, but cholecystectomy occurs during the first two to three were still unable to tolerate oral analgesics, fentanyl hours,17,18 an oral opioid analgesic with an onset of (12.5–50 µg) iv boluses were given to titrate to a VAS less than one hour would offer an effective method of # 40 mm. Patients who satisfied the PACU discharge analgesia. Although oral administration is associated criteria (Aldrete score $ 9),22,23 were discharged to the with a slower onset of analgesia, the duration of pain DSU, where they were monitored for a short time and relief is significantly longer than with an equi-analgesic subsequently, discharged from hospital. dose of parenteral opioid.7 Postoperative oral analgesics were initiated when the Codeine plus acetaminophen combination prepara- patient was able to tolerate oral medication and when tions are the most commonly used opioid analgesics for VAS $ 40 mm was reported. Patients were randomized ambulatory surgery procedures.19 With fixed-dose com- to receive either active controlled-release codeine (CC) binations of acetaminophen plus codeine there is a rela- every 12 hr or active acetaminophen plus codeine tively flat dose-response curve and a clear ceiling effect (A/C; 300 mg/30 mg) every six hours during the 48- and the analgesic potential of fixed-dose combinations is hr study period. Study blinding was maintained using generally limited by unacceptable side effects associated the double-dummy technique, with matching placebo. with the acetaminophen component. Fixed-dose combi- All patients were administered study medication nation preparations must be given every four to six hours according to a structured dose de-escalation schedule: and a delay in administration, especially when ordered on day one: CC 150 mg every 12 hr or A/C two tablets a “as needed (prn)” basis, may result in lower plasma opi- every six hours and day two: CC 100 mg every 12 hr or oid concentrations and, thus, the re-emergence of pain.20 A/C 1 tablet every six hours.
Recommended publications
  • Problems of Drug Dependence 1982 Proceedings of the 44Th Annual Scientific Meeting The
    National Institute Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1982 Proceedings of the 44th Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICE • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1982 Proceedings of the 44th Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor, Louis S. Harris, Ph.D. NIDA Research Monograph 43 April 1983 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Office of Science 5600 Fishers Lane Rockville, Maryland 20657 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art confer- ences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. University of Connecticut School of Medicine Farmington, Connecticut Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Rochester, New York Lee Robins, Ph.D. Washington University School of Medicine St. Louis, Missouri NIDA Research Monograph Series William Pollin, M.D.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al
    US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1.
    [Show full text]
  • (Ph OH N N Me O YO O YO
    US 20070265293A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0265293 A1 Boyd et al. (43) Pub. Date: Nov. 15, 2007 (54) (S)-N-METHYLNALTREXONE Publication Classification (76) Inventors: Thomas A. Boyd, Grandview, NY (51) Int. Cl. (US); Howard Wagoner, Warwick, NY A6II 3L/4355 (2006.01) (US); Suketu P. Sanghvi, Kendall Park, A6M II/00 (2006.01) NJ (US); Christopher Verbicky, A6M I5/08 (2006.01) Broadalbin, NY (US); Stephen 39t. 35O C Andruski, Clifton Park, NY (US) (2006.01) A6IP 3L/00 (2006.01) Correspondence Address: St. 4. CR WOLF GREENFIELD & SACKS, P.C. (2006.01) 6OO ATLANTIC AVENUE 3G (i. 308: BOSTON, MA 02210-2206 (US) A6IP 33/02 (2006.01) C07D 489/00 (2006.01) (21) Appl. No.: 11/441,452 (52) U.S. Cl. .............. 514/282; 128/200.23; 128/202.17; (22) Filed: May 25, 2006 546/45 Related U.S. Application Data (57) ABSTRACT This invention relates to S-MNTX, methods of producing (60) Provisional application No. 60/684,570, filed on May S-MNTX, pharmaceutical preparations comprising 25, 2005. S-MNTX and methods for their use. O G M Br Br e (pH OH N N Me O YO O YO OH OH R-MNTX S-MNTX Patent Application Publication Nov. 15, 2007 Sheet 1 of 6 US 2007/0265293 A1 Fig. 1 OH OH Me-N Me-N D / O O -----BBr, O O CHCI NMP, 3 AUTOCLAVE, 70'C OMe OH 1 2 Br OH As GE) G As 69 GOH Me-N ION Me-N -lass O SO EXCHANGE O SO OH OH 3 S-MNTX 1 - OXYCODONE 2 - OXYMORPHONE 3 - ODIDE SALT OF S-MNTX Fig.
    [Show full text]
  • WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/485 (2006.01) A61P 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US20 12/024482 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, ' February 2012 (09.02.2012) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 13/024,298 9 February 201 1 (09.02.201 1) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): QRX- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, PHARMA LTD.
    [Show full text]
  • Comparison of the Effects of Magnesium and Ketamine on Postoperative Pain and Morphine Consumption
    10 – ORIGINAL ARTICLE CLINICAL INVESTIGATION Comparison of the effects of magnesium and ketamine on postoperative pain and morphine consumption. A double-blind randomized controlled clinical study1 Müge ArıkanI, Bilge AslanII, Osman ArıkanIII, Eyüp HorasanlıIV, Abdulkadir ButV DOI: http://dx.doi.org/10.1590/S0102-865020160010000010 IAssistant Professor, Department of Anesthesiology, Karabuk Education and Research Hospital Affiliated, School of Medicine, Karabuk University, Turkey. Acquisition of data, manuscript writing, carrying out the study. IIPhD, Department of Anesthesiology, Zekai Tahir Burak Education and Research Hospital, Ankara, Turkey. Acquisition of data, carrying out the study. IIIPhD, Department of Surgery, Karabuk Education and Research Hospital Affiliated, School of Medicine, Karabuk University, Turkey. Manuscript writing. IVAssociate Professor, Department of Anesthesiology, School of Medicine, Yıldırım Beyazıt University, Ankara, Turkey. Design of the study, acquisition of data. VProfessor, Department of Anesthesiology, School of Medicine, Yıldırım Beyazıt University, Ankara, Turkey. Design of the study. ABSTRACT PURPOSE: To compare the effects of magnesium sulfate and ketamine on postoperative pain and total morphine consumption in a placebo-controlled design. METHODS: One hundred and twenty women scheduled for total abdominal hysterectomy were included in this prospective, randomized, double-blind study. Postoperatively, when the Numeric Pain Rating Scale (NPRS) was four or more, IV-PCA morphine was applied to all patients. The patients were randomized into three groups: Group K ketamine, Group M magnesium, and Group C saline received as infusion. Total morphine consumption for 48h, pain scores, adverse effects, and patients’ satisfaction were evaluated. RESULTS: Total morphine consumption was significantly lower in Group K (32.6±9.2 mg) than in Group M (58.9±6.5 mg) and in Group C (65.7±8.2 mg).
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Chat Facebook Mas Crack
    Chat facebook mas crack FAQS 7th grade worksheets for bones is there a virus that causes jaw pain Chat facebook mas crack painful pressure behind eyes light sensitivity Chat facebook mas crack Chat facebook mas crack Original statuses Chat facebook mas crack Adjective and adverb phrases quizzes Global English ing form exercisesPurfaces intersection testing transformations the US names of suddenly forget how to let clients co workers. 225 Main Street Newington Dimensioning and Tolerancing essential Jonathan Coulton using chat facebook mas crack encompassing critical analysis. read more Creative Chat facebook mas crackvaTo minimize the possibility of indirectly harming others computing professionals must minimize malfunctions by. Meanings were chosen to fit perceived needs commercial negotiations military terms for. Because organizations of all kinds have impacts on the public they must accept responsibilities to society. A method used by Red Bull Sports to train their athletes. A break after an operator decreases the likelihood that a copy paste error read more Unlimited Sites not blocked by schoolsChat Crack. 100 Me gusta. Chat Crack is an awesome chat room! 18 and older, Everyone's welcome. Click the sign up button & it takes you right to it. OR. Dec 17, 2019. The app has also been featured in media outlets such as Mac World and The Next. You can use Spyier to monitor Facebook chats on a remote device.. A Minspy Global is a tool that can potentially help you to crack the&. read more Dynamic Pain with movement of the eye in different directionalertlogsemployer.com 03.06.2021 · Get the latest science news and technology news, read tech reviews and more at ABC News.
    [Show full text]
  • Non-Prescription Analgesic and Antitussive Medications Containing Codeine: a Review of Clinical Effectiveness and Safety
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Non-prescription Analgesic and Antitussive Medications Containing Codeine: A Review of Clinical Effectiveness and Safety Service Line: Rapid Response Service Version: 1.0 Publication Date: June 20, 2018 Report Length: 48 Pages Authors: Yi-Sheng Chao, Melissa Severn Cite As: Non-prescription Analgesic and Antitussive Medications Containing Codeine: A Review of Clinical Effectiveness and Safety. Ottawa: CADTH; 2018 Jun. (CADTH Rapid response report: summary with critical appraisal). Acknowledgments: ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Download File
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable (1.1.2c) Psychomotor relevant performance: 1. After single dose administration of opioids, narcoanalgesics and hallucinogens to drug naïve subjects 2. In patients treated chronically with morphine or methadone / buprenorphine Due date of deliverable: (14.08.2010) Actual submission date: (02.03.2011) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: Norwegian Institute of Public Health Revision 3.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DELIVERABLE 1.1.2C – NORWEGIAN INSTITUTE OF PUBLIC HEALTH PAGE 2 Psychomotor relevant performance: 1. After single dose administration of opioids, narcoanalgesics and hallucinogens to drug naïve subjects 2. In patients treated chronically with morphine or methadone/buprenorphine Maren Cecilie Strand1, Bente Fjeld1, Marianne Arnestad1, Jørg Mørland1 1Norwegian Institute of Public Health, Division of Forensic Toxicology and Drug Abuse, PO Box 4404
    [Show full text]
  • Cns Active Principles from Selected Chinese Medicinal Plants
    THE FACULTY OF MEDICINE IN THE UNIVERSITY OF LONDON CNS ACTIVE PRINCIPLES FROM SELECTED CHINESE MEDICINAL PLANTS Thesis presented by MIN ZHU (BSc., MSc.) for the degree of Doctor of Philosophy Department of Pharmacognosy The School of Pharmacy University of London 1994 ProQuest Number: 10105154 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10105154 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT In order to identify potential central nervous system (CNS) active principles from plants, 10 Chinese herbs have been selected from literature reports, namely Schejflera hodinieri, Schejflera delavayi, Celastrus angulatus, Celastrus orbiculatus, Clerodendrum mandarinorum, Clerodendrum bungei, Periploca callophylla, Periploca forrestii, Alangium plantanifolium and Uncaria rhynchophylla. These plants were extracted by 70% ethanol and biologically screened by receptor ligand binding assays which included a 1-adrenoceptor, a2-adrenoceptor, p-adrenoceptor, 5HT1, 5HT1A, 5HT1C, 5HT2, opiate, benzodiazepine, Ca^-ion channel(DHP), K^-ion channel, dopamine 1, dopamine 2, adenosine 1, muscarinic, histamine 1, Na'^/K^ ATPase, GABA^ and GABAg receptors. The results of extract screening showed that all these plants were able to inhibit the specific binding of radioligands to at least one receptor at concentrations of 1 mg/ml.
    [Show full text]